| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) University of Pennsylvania |
| Information provided by: | National Institute on Drug Abuse (NIDA) |
| ClinicalTrials.gov Identifier: | NCT00000353 |
Purpose
The purpose of this study is to determine the efficacy and safety of a buprenorphine/naloxone sublingual tablet formulation as an office-based therapy for opiate dependence treatment.
| Condition | Intervention | Phase |
|
Opioid-Related Disorders Substance-Related Disorders |
Drug: Buprenorphine/naloxone |
Phase II |
| Drug Information available for: | Naloxone Naloxone hydrochloride Buprenorphine Buprenorphine hydrochloride |
| Study Type: | Interventional |
| Study Design: | Treatment |
| Official Title: | Efficacy/Safety Trial of Buprenorphine/Nx for Opiate Dependence |
Eligibility
| Ages Eligible for Study: | 19 Years to 57 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Please contact site for information.
Contacts and Locations| United States, Pennsylvania | |||||
| University of Pennsylvania | |||||
| Philadelphia, Pennsylvania, United States, 19104 6178 | |||||
| National Institute on Drug Abuse (NIDA) |
| University of Pennsylvania |
| Principal Investigator: | Charles O'Brien, M.D., Ph.D. | PDVAMC Treatment Research Center |
More Information
| Study ID Numbers: | NIDA-3-0012-2, Y01-3-0012-2 |
| First Received: | September 20, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00000353 |
| Health Authority: | United States: Federal Government |
|
|
|
|
|
